Ketamine inj (ketamine): Uses, Dosage & Side Effects

What it's for (Indications)

Ketamine is a highly versatile medication primarily indicated for the induction and maintenance of anesthesia, particularly in situations where hemodynamic stability is crucial or when conventional anesthetic agents are contraindicated.
It is renowned for producing a unique state of 'dissociative anesthesia,' characterized by profound analgesia, amnesia, and a trance-like cataleptic state, while generally maintaining pharyngeal-laryngeal reflexes and stable cardiovascular function.
Beyond its well-established role in general anesthesia, ketamine has gained significant recognition for several off-label, yet clinically validated, applications.
These include the rapid treatment of severe, acute pain, especially neuropathic pain conditions like Complex Regional Pain Syndrome (CRPS) and phantom limb pain, where conventional analgesics are often inadequate.
Furthermore, low-dose intravenous ketamine infusions have emerged as a rapid-acting antidepressant treatment for individuals suffering from treatment-resistant depression (TRD) and acute suicidal ideation, offering symptom relief within hours rather than weeks.
It is also utilized in emergency medicine for procedural sedation, as an antiepileptic agent in refractory status epilepticus when other treatments have failed, and its utility extends to situations requiring bronchodilation in severe, refractory asthma dueid its sympathomimetic properties.
This broad spectrum of action underscores its critical role in modern clinical practice.

Dosage Information

Type	Guideline
Standard	The dosage of ketamine is highly individualized, contingent upon the specific indication, patient's age, weight, overall health status, and the chosen route of administration. For intravenous (IV) induction of anesthesia, a typical adult dose ranges from 1 to 4.5 mg/kg, administered slowly over 60 seconds to mitigate potential dose-dependent side effects such as respiratory depression. For intramuscular (IM) induction of anesthesia, doses generally range from 6.5 to 13 mg/kg. Maintenance of anesthesia often involves continuous IV infusions at rates varying from 0.5 to 2 mg/kg/hour, or intermittent boluses as needed, titrating to the desired level of anesthesia. In the context of treatment-resistant depression (TRD) or acute suicidal ideation, subanesthetic IV ketamine infusions are typically administered at a dose of 0.5 mg/kg over 40 minutes, with subsequent dosing regimens tailored to individual patient response and tolerability, often delivered in a series of treatments. For chronic pain management, significantly lower, sub-dissociative doses are employed, frequently ranging from 0.1 to 0.2 mg/kg/hour via continuous IV infusion, sometimes combined with a loading bolus. When utilized for procedural sedation or acute agitation in emergency settings, doses typically fall within the IM range of 4-5 mg/kg or IV range of 1-2 mg/kg. Careful titration, continuous monitoring of vital signs, and close observation of patient response are paramount across all indications to ensure both efficacy and patient safety.

Type

Guideline

Standard

The dosage of ketamine is highly individualized, contingent upon the specific indication, patient's age, weight, overall health status, and the chosen route of administration. For intravenous (IV) induction of anesthesia, a typical adult dose ranges from 1 to 4.5 mg/kg, administered slowly over 60 seconds to mitigate potential dose-dependent side effects such as respiratory depression. For intramuscular (IM) induction of anesthesia, doses generally range from 6.5 to 13 mg/kg. Maintenance of anesthesia often involves continuous IV infusions at rates varying from 0.5 to 2 mg/kg/hour, or intermittent boluses as needed, titrating to the desired level of anesthesia. In the context of treatment-resistant depression (TRD) or acute suicidal ideation, subanesthetic IV ketamine infusions are typically administered at a dose of 0.5 mg/kg over 40 minutes, with subsequent dosing regimens tailored to individual patient response and tolerability, often delivered in a series of treatments. For chronic pain management, significantly lower, sub-dissociative doses are employed, frequently ranging from 0.1 to 0.2 mg/kg/hour via continuous IV infusion, sometimes combined with a loading bolus. When utilized for procedural sedation or acute agitation in emergency settings, doses typically fall within the IM range of 4-5 mg/kg or IV range of 1-2 mg/kg. Careful titration, continuous monitoring of vital signs, and close observation of patient response are paramount across all indications to ensure both efficacy and patient safety.

Safety & Warnings

Common Side Effects

Patients may experience hypertension (increased blood pressure), tachycardia (increased heart rate), hallucinations, complete loss of sensation, nausea, vomiting, swelling at injection site, bleeding at injection site, and redness at injection site.

Serious Warnings

Black Box Warning: WARNINGS: RESPIRATORY DEPRESSION, PSYCHOTOMIMETIC EFFECTS, CARDIOVASCULAR COMPLICATIONS, AND POTENTIAL FOR ABUSE. Ketamine administration can lead to significant respiratory depression, particularly when given rapidly intravenously or in conjunction with other central nervous system depressants. Patients must be closely monitored for respiratory function, and resuscitative equipment should be immediately available. Furthermore, emergent psychological reactions, including vivid dreams, hallucinations, delirium, and confusion, are common during recovery from ketamine anesthesia, especially in adults. These psychotomimetic effects can be severe and require careful patient monitoring in a controlled environment. Ketamine also frequently causes increases in blood pressure and heart rate, which necessitates cautious use in individuals with hypertension, cardiac insufficiency, or other cardiovascular compromise where such increases would pose a significant risk. Finally, ketamine has a known potential for abuse and psychological dependence. Due to these serious risks, ketamine should only be administered by or under the direct supervision of an anesthesiologist or other healthcare professional trained in its use and in the management of adverse reactions, in a setting equipped for continuous monitoring and resuscitation.
Administration: Must be administered by an experienced medical professional only.
Hypersensitivity: Inform your doctor if you are allergic to ketamine before any medical procedures.
Storage: Store at room temperature away from direct heat and sunlight.
Keep out of the reach of children and pets.
Pregnancy: No definite data regarding use in pregnant females; consult your doctor before use.
Lactation: Research suggests women who are breastfeeding should avoid this medicine; consult your doctor before use.
Driving: Avoid driving as it may affect ability to drive.
Alcohol: Avoid consuming alcohol.
Respiratory Depression: Rapid administration or overdose may cause respiratory depression (lowered breathing rate).

How it Works (Mechanism of Action)

Ketamine exerts its primary pharmacological effects through its action as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a type of ionotropic glutamate receptor. By binding to a site within the NMDA receptor's ion channel, ketamine effectively blocks the influx of calcium ions, thereby inhibiting the excitatory neurotransmitter glutamate. This blockade is central to its dissociative anesthetic properties, leading to a functional dissociation between the limbic and cortical systems, resulting in the characteristic trance-like state, profound analgesia, and amnesia. Beyond its well-established NMDA antagonism, ketamine also interacts with a multitude of other neuroreceptors and neurotransmitter systems, contributing to its diverse clinical profile. It acts as a weak agonist at opioid receptors (mu, delta, and kappa), which contributes to its potent analgesic effects. Furthermore, ketamine inhibits the reuptake of monoamines such as dopamine, norepinephrine, and serotonin, and acts as an antagonist at muscarinic cholinergic receptors. These broader neurochemical interactions are implicated in its antidepressant and psychotomimetic effects. In the context of depression, NMDA receptor blockade is thought to rapidly induce a cascade of intracellular signaling events, including the activation of the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptogenesis and restoration of dendritic spine density in prefrontal cortical neurons, thereby enhancing synaptic plasticity and rapidly alleviating depressive symptoms. These multi-faceted actions underscore ketamine's unique pharmacological fingerprint.